Citations

Mayo Clinic

Showing 10 of 108599 citations.

Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Ettinger, David S. , Wood, Douglas E. , Stevenson, James, Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , DeCamp, Malcolm M., Dilling, Thomas J. , Dowell, Jonathan E. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hughes, Miranda, Bharat, Ankit , Chang, Joe Y. , Chirieac, Lucian R. , Grotz, Travis E. , Hegde, Aparna , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Journal of the National Comprehensive Cancer Network | September 6, 2023 | Volume: 21 | Issue: 9 | Pages: 961-979

10.6004/jnccn.2023.0045 | PMID 37673108 Get It

Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM). The NCCN Guidelines for PeM provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated PeM. The diagnosis of PeM may be delayed because PeM mimics other diseases and conditions and because the disease is so rare. The pathology section was recently updated to include new information about markers used to identify mesothelioma, which is difficult to diagnose. The term “malignant” is no longer used to classify mesotheliomas, because all mesotheliomas are now defined as malignant.
Rechallenge With Switching Immune Checkpoint Inhibitors Following Autoimmune Myocarditis in a Patient With Lynch Syndrome
Eslinger, Cody , Walden, Daniel , Barry, Timothy , Shah, Shimoli , Samadder, N. Jewel , Bekaii‐Saab, Tanios , Samadder, Niloy Jewel, Bekaii-Saab, Tanios S

Journal of the National Comprehensive Cancer Network | September 6, 2023 | Volume: 21 | Issue: 9 | Pages: 894-899

10.6004/jnccn.2023.7029 | PMID 37673116 Get It

Immune checkpoint inhibitors (ICIs) induce profound benefits in cancer patients with mismatch repair gene mutations or high levels of microsatellite instability. Herein, we present a case of a patient with history of Muir-Torre/Lynch syndrome and metastatic gastric adenocarcinoma in the presence of an MSH2 gene mutation. The patient was initially treated with a PD-1 inhibitor, pembrolizumab, but developed grade 4 myocarditis requiring treatment with infliximab and a prolonged steroid taper. Following discontinuation of pembrolizumab, surveillance testing showed no radiographic or endoscopic evidence of progression for 7 months, until biopsy results from a repeat upper endoscopy indicated local disease recurrence. The patient was subsequently rechallenged with another PD-1 inhibitor, nivolumab, at a 50% dose reduction without recurrent adverse events and eventually achieved a complete response after 13 cycles. This case highlights the relative importance of considering careful rechallenge with ICI therapy in patients with microsatellite instability–high malignancies and a high risk of severe adverse events.
NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023
Bevers, Therese B. , Niell, Bethany L. , Bonaccio, Ermelinda, Camp, Melissa , Chikarmane, Sona A. , Eghtedari, Mohammad , Flanagan, Meghan R. , Hawley, Jeffrey , Helvie, Mark A. , Hodgkiss, Linda, Hoyt, Tamarya L., Ivanovich, Jennifer , Kulkarni, Swati , Lancaster, Rachael, Mauer, Caitlin , Pearlman, Mark D. , Philpotts, Liane E. , Plichta, Jennifer K. , Shakeri, Shadi Aminololama, Smith, Mary Lou , Streibert, Clarie L., Strigel, Roberta M. , Tumyan, Lusine , Winkler, Nicole , Wolverton, Dulcy , Bergman, Mary Anne, Stehman, Katie, Plichta, Jennifer K , Baker, Jennifer L. , Bennett, Debbie Lee , Conant, Emily F. , Jochelson, Maxine S. , Maxwell, Jessica, Patel, Bhavika , Plecha, Donna , Kumar, Rashmi

Journal of the National Comprehensive Cancer Network | September 6, 2023 | Volume: 21 | Issue: 9 | Pages: 900-909

10.6004/jnccn.2023.0046 | PMID 37673117 Get It

The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. The NCCN Breast Cancer Screening and Diagnosis Panel is composed of a multidisciplinary team of experts in the field, including representation from medical oncology, gynecologic oncology, surgical oncology, internal medicine, family practice, preventive medicine, pathology, diagnostic and interventional radiology, as well as patient advocacy. The NCCN Breast Cancer Screening and Diagnosis Panel meets at least annually to review emerging data and comments from reviewers within their institutions to guide updates to existing recommendations. These NCCN Guidelines Insights summarize the panel’s decision-making and discussion surrounding the most recent updates to the guideline’s screening recommendations.
Parvalbumin-Positive Neurons in the Globus Pallidus Externus Modulate Task-Irrelevant Behaviors to Balance Exploration and Exploitation
Kang, Shinwoo , Yang, Minsu Abel , Bruce, Robert, Song, Minryung , Bruce, Robert, Choi, Doo‐Sup , Lee, Sang Wan

2023 Conference on Cognitive Computational Neuroscience | September 6, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.32470/ccn.2023.1450-0 Get It

Editorial Comment: When Will Coronary Artery Stent Imaging Be Ready for Prime Time?
Bowman, Andrew W.

American Journal of Roentgenology | September 6, 2023 | Volume: 221 | Issue: 5 | Pages: 610-610

10.2214/ajr.23.29857 | PMID 37404087 Get It

Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study
Desai, Aakash , Hashash, Jana G. , Kochhar, Gursimran , Hashash, Jana G , Desai, Aakash , Farraye, Francis A.

Crohn's & Colitis 360 | September 6, 2023 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/crocol/otad047 | PMID 37680248 Get It

Abstract Background Tixagevimab and cilgavimab (Evusheld) are 2 fully human monoclonal antibodies that received emergency-use authorization on December 21, 2021, for pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in patients who are moderate–severely immunocompromised. The real-world efficacy of Evusheld in patients with inflammatory bowel disease (IBD) is not known. Methods We conducted a retrospective cohort study using TriNetX, a multi-institutional database in patients with IBD who received Evusheld compared to patients with IBD who did not receive Evusheld (12.1.2021–10.28.2022). The primary outcome was to assess the risk of COVID-19 within 6 months. One-to-one propensity score matching (PSM) was performed for demographic parameters, comorbid conditions, IBD medications, and history of COVID-19. Risk was expressed as adjusted odds ratio (aOR) with 95% confidence interval (CI). Results Four hundred and eight patients (0.19%) with IBD received Evusheld (mean age 58.6 ± 15.4 years old, female 47.7%) during the study period. After PSM, there was no difference in the risk (aOR 0.88, 95% CI, 0.33–2.35) of COVID-19 in the Evusheld cohort compared to the IBD control cohort. No patients required ICU care or intubation/respiratory support or were deceased in the Evusheld cohort. Conclusions Our study did not show that Evusheld decreases the risk of COVID-19 in patients with IBD. Prevention of moderate–severe COVID-19 in these patients should focus on vaccination strategies and early COVID-19 therapies.
Implementing a Sports Ultrasound Curriculum in Undergraduate Medical Education
Schroeder, Allison N. , Amin, Idris, Bowen, Brady J., Callender, Shelley Street, Ferderber, Megan , Kerr, Hamish , Phillips, Shawn, Romero, Joshua , Rudolph, Lauren, Vidlock, Kathryn , Waterbrook, Anna L., Kruse, Ryan C. , Bowen, Brady J.

Current Sports Medicine Reports | September 6, 2023 | Volume: 22 | Issue: 9 | Pages: 328-335

10.1249/jsr.0000000000001099 | PMID 37678352 Get It

Abstract The utilization of sports ultrasound in the clinical practice of sports medicine physicians is growing rapidly. Simultaneously, ultrasound is being increasingly implemented as a teaching tool in undergraduate medical education. However, a sports ultrasound curriculum for medical students has not been previously described. In this article, we describe methods as well as barriers to implementing a sports ultrasound curriculum at the medical school level. Recommended content for the curriculum also is discussed. While educational goals and resources will vary among institutions, this article may serve as a general roadmap for the creation of a successful curriculum.
A Paradigm Shift in Heart Preservation: Improved Post-transplant Outcomes in Recipients of Donor Hearts Preserved With the SherpaPak System
Shudo, Yasuhiro , Leacche, Marzia , Copeland, Hannah , Molina, Ezequiel , Schroder, Jacob N. , Sciortino, Christopher M., Kawabori, Masashi , D’Alessandro, David A. , Pham, Si M. , Silvestry, Scott , Jacobs, Jeffrey P. , Meyer, Dan M , Zuckermann, Andreas Oliver

ASAIO Journal | September 6, 2023 | Volume: 69 | Issue: 11 | Pages: 993-1000

10.1097/mat.0000000000002036 | PMID 37678260 Get It

Traditional ice storage has been the historic standard for preserving donor’s hearts. However, this approach provides variability in cooling, increasing risks of freezing injury. To date, no preservation technology has been reported to improve survival after transplantation. The Paragonix SherpaPak Cardiac Transport System (SCTS) is a controlled hypothermic technology clinically used since 2018. Real-world evidence on clinical benefits of SCTS compared to conventional ice cold storage (ICS) was evaluated. Between October 2015 and January 2022, 569 US adults receiving donor hearts preserved and transported either in SCTS (n = 255) or ICS (n = 314) were analyzed from the Global Utilization And Registry Database for Improved heArt preservatioN (GUARDIAN-Heart) registry. Propensity matching and a subgroup analysis of >240 minutes ischemic time were performed to evaluate comparative outcomes. Overall, the SCTS cohort had significantly lower rates of severe primary graft dysfunction (PGD) ( p = 0.03). When propensity matched, SCTS had improving 1-year survival ( p = 0.10), significantly lower rates of severe PGD ( p = 0.011), and lower overall post-transplant MCS utilization ( p = 0.098). For patients with ischemic times >4 hours, the SCTS cohort had reduced post-transplant MCS utilization ( p = 0.01), reduced incidence of severe PGD ( p = 0.005), and improved 30-day survival ( p = 0.02). A multivariate analysis of independent risk factors revealed that compared to SCTS, use of ice results in a 3.4-fold greater chance of severe PGD ( p = 0.014). Utilization of SCTS is associated with a trend toward increased post-transplant survival and significantly lower severe PGD and MCS utilization. These findings fundamentally challenge the decades-long status quo of transporting donor hearts using ice.
Stem-like CD4 + T cells in perivascular tertiary lymphoid structures sustain autoimmune vasculitis
Sato, Yuki , Jain, Abhinav , Ohtsuki, Shozo , Okuyama, Hirohisa , Sturmlechner, Ines , Takashima, Yoshinori , Le, Kevin , Bois, Melanie C. , Berry, Gerald J. , Goronzy, Jörg J. , Weyand, Cornelia M. , Le, Kevin-Phu C , Goronzy, Jorg , Weyand, Cornelia , Jain, Abhinav , Berry, Gerald J , Sturmlechner, Ines , Warrington, Kenneth J.

Science Translational Medicine | September 6, 2023 | Volume: 15 | Issue: 712 | Pages: No page available

10.1126/scitranslmed.adh0380 | PMID 37672564 Get It

Autoimmune vasculitis of the medium and large elastic arteries can cause blindness, stroke, aortic arch syndrome, and aortic aneurysm. The disease is often refractory to immunosuppressive therapy and progresses over decades as smoldering aortitis. How the granulomatous infiltrates in the vessel wall are maintained and how tissue-infiltrating T cells and macrophages are replenished are unknown. Single-cell and whole-tissue transcriptomic studies of immune cell populations in vasculitic arteries identified a CD4 + T cell population with stem cell–like features. CD4 + T cells supplying the tissue-infiltrating and tissue-damaging effector T cells survived in tertiary lymphoid structures around adventitial vasa vasora, expressed the transcription factor T cell factor 1 (TCF1), had high proliferative potential, and gave rise to two effector populations, Eomesodermin (EOMES) + cytotoxic T cells and B cell lymphoma 6 (BCL6) + T follicular helper-like cells. TCF1 hi CD4 + T cells expressing the interleukin 7 receptor (IL-7R) sustained vasculitis in serial transplantation experiments. Thus, TCF1 hi CD4 + T cells function as disease stem cells and promote chronicity and autonomy of autoimmune tissue inflammation. Remission-inducing therapies will require targeting stem-like CD4 + T cells instead of only effector T cells.
Clinical Review Primary Care Diagnosis of Thyroid Disease
Behnia, Mehrdad , Gharib, Hossein

Hospital Practice | September 6, 2023 | Volume: 31 | Issue: 6 | Pages: 121-134

10.1080/23771003.1996.12314900 Get It